California Passes Bill to Claim Ownership of Prescription Drugs
On Monday (8/31), a bill was passed in California, with 32 in favor and 7 against, to redistribute the state’s market power to make prescription drugs more affordable and accessible. The COVID-19 pandemic has been said to act as proof that improvements must be made to...
FDA Approves Expansion of Remdesivir for Hospitalized COVID-19 Patients
Gilead, a research-based biopharmaceutical company, has reported that their new antiviral treatment for COVID-19 Remdesivir, has just been granted an expansion on emergency use authorization (EUA) by the FDA for all patients hospitalized due to COVID-19. Originally...
FDA Grants Approval to Laurent Pharmaceuticals to Start COVID-19 Phase 2 Clinical Trial in the United States
Laurent Pharmaceuticals, a Montreal based clinical stage biopharmaceutical company has come up with an oral drug candidate, LAU-7b, to potentially treat COVID-19. The U.S. Food and Drug Administration (FDA) has granted Laurent Pharmaceuticals to begin enrolling U.S....
RenalytixAI FDA Clearence for New Kidney Treatment Technology
RenalytixAI, an in vitro diagnostics that uses artificial intelligence, has filed a submission to the FDA to clear new kidney treatment called KidneyIntelx. KidneyIntelx is designed to optimize clinical management and patient outcomes of kidney disease research as...
EPA Grants Emergency Approval for Antiviral Coating to be Used for American Airlines
American Airlines has been given approval by the U.S. Environmental Protection Agency (EPA) to use a COVID-19 disinfectant on surfaces throughout the airplanes. The virus-killing spray is effective on surfaces for up to seven days, and the EPA is studying whether this...
Health Canada Implements ICH Pediatric Drug Development Guidance
Health Canada has adopted a nonclinical safety testing guidance to help develop medication in pediatrics. This guidance called GuidanceS11: Nonclinical Safety Testing in Support of Development of Pediatric Medicines has been developed by the ICH and is slated to be...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com